Inflammatory and Autoimmune Diseases
An Introduction to Autoimmune diseases
Autoimmunity and deregulation of the immune system contribute to many skin diseases, including systemic sclerosis, dermatomyositis, psoriasis, vitiligo, alopecia areata and lichen sclerosus; inflammatory diseases such as hidradenitis suppurativa, allergic contact dermatitis and atopic eczema; and autoimmune blistering diseases, including pemphigus vulgaris, bullous pemphigoid, epidermolysis bullosa acquisita and dermatitis herpetiformis. Established treatments for autoimmune diseases include systemic corticosteroids and immunosuppressive therapies, while new therapies in development include biologic therapies targeting cytokines such as tumour necrosis factor alpha and interleukins (ILs) IL-23 and IL-17; enzymes such as Janus kinase-1 (JAK-1); and the regulatory protein-retinoic acid receptor-related-orphan-receptor-gamma t (RORÎłt).
Our supporting partners do not constitute an endorsement of the content on this page.
What did the Women’s Dermatologic Society bring to EADV 2026? Explore session highlights spanning blistering diseases, skin cancer, scarring alopecias, and more. Prof. Dedee Murrell introduces the society’s focus on mentorship, explains why the session is worth watching, and shares why dermatologists should consider joining.
What were the key dermatology updates at EADV 2026? Dr Melinda Gooderham shares her highlights, exploring the Janus kinase (JAK) inhibitors session, new data comparing zasocitinib with deucravacitinib, and 2-year findings from ICONIC-TOTAL evaluating icotrokinra.
Part B of the phase 2 APEX trial evaluated three zumilokibart dosing regimens in adults with moderate-to-severe atopic dermatitis. All three met the primary endpoint at Week 16, with findings supporting mid dose selection for phase 3. Dr Melinda Gooderham discusses the efficacy and safety results from both Part A and Part B and what they could mean for clinical practice and those living with AD.
Could abdakibart offer a new treatment option for hidradenitis suppurativa? Dr Martina L. Porter discusses encouraging findings from the phase 2 LOTUS trial, including improvements in disease severity and draining tunnels, alongside a reassuring safety profile over 16 weeks, and considers what these results could mean for clinical practice.
For women taking dupilumab to manage atopic dermatitis or asthma, limited pregnancy safety data can make treatment decisions challenging. Dr Christina Chambers discusses reassuring findings from a registry study of 539 pregnancies and how they could help clinicians counsel women who are pregnant or planning a family.
Sonelokimab showed encouraging results in the phase 2 LEDA trial in adults with palmoplantar pustulosis. Dr Nina Magnolo discusses the findings, including a mean 64% reduction in disease severity at Week 16, and their potential implications for patients.
On Day 2 of the EADV 2026 congress, we were delighted to speak with touchDERMATOLOGY Editorial Board member, Dr Maria Angeliki Gkini who shared her highlights from key psoriasis sessions and discussed what these developments could mean for clinical practice.
New 52-week REZOLVE-AD data showed durable responses with monthly and quarterly rezpegaldesleukin (REZPEG) maintenance dosing in atopic dermatitis. Prof. Thomas Bieber discusses the findings and the potential for long-term remission and disease modification, highlighting the further evidence needed to explore these goals.
How does bimekizumab perform in everyday clinical practice? An Italian multicenter study reported improvements in disease activity, pain, and quality of life in people with hidradenitis suppurativa, with no unexpected safety signals. Dr Mario Valenti shares the findings and his perspective with touchDERMATOLOGY.
Encouraging findings from JAKPPPOT support the feasibility of a definitive randomized controlled trial of Janus kinase inhibitors in palmoplantar pustulosis and provide an exploratory estimate of treatment effect. We spoke with Dr David Gleeson about the results presented at EADV 2026 and their implications for future research.
Dr Maria-Angeliki Gkini explores the growing role of psychodermatology in supporting patients’ wider needs, alongside emerging technologies and approaches that could shape the future management of psoriatic disease.
We are delighted to announce Dr Dennis Niebel as a touchDERMATOLOGY Future Leader 2026, selected for his contributions to immune-mediated skin disorders and sustainable dermatology. Germany-based Dr Dennis Niebel is a Lecturer and Consultant Dermatologist at the University of Cologne (Cologne, ...
We are delighted to announce Dr Dimitri Luz as a touchDERMATOLOGY Future Leader 2026. Dr Luz is helping to advance immune-mediated dermatology through his work in clinical care, research, and medical education. A Brazilian-trained dermatologist now based in Perth, Australia, his ...
We are delighted to introduce Dr Olufolakemi Cole-Adeife as a touchDERMATOLOGY Future Leader 2026. Dr Cole-Adeife is a Consultant Physician, Dermatologist and Venereologist at Lagos State University Teaching Hospital (LASUTH) and a Lecturer at Lagos State University College of Medicine in ...
We are delighted to introduce Dr Benjamin Ungar as a touchDERMATOLOGY Future Leader 2026. Dr Ungar is an Assistant Professor of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, USA, where he is Director of the ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
